Search results for "skin and connective tissue diseases"

showing 10 items of 838 documents

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct

Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer

2005

In this retrospective study we assessed the expression of the HER2/neu oncogene product in a series of 574 consecutive breast cancer cases, all recruited at the Maurizio Ascoli Cancer Center of Civico Hospital, in Palermo, between January 1998 and June 2003. The HER2/neu expression was evaluated using immunohistochemistry and scored from 0 to +3 as per FDA recommendations. The HER2/neu expression levels were related to the clinical-pathological features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors, and hormonal or chemotherapeutic treatment. In 108 patients with a follow-up period of 3 years or more, the HER2/neu expression was also …

AdultOncologymedicine.medical_specialtyTime FactorsReceptor ErbB-2medicine.drug_classBreast NeoplasmsDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular BiologyHER2/neuBreast cancerHistory and Philosophy of ScienceInternal medicineBiomarkers TumormedicineHumansNeoplasm Metastasisskin and connective tissue diseasesPathologicalIn Situ Hybridization FluorescenceAgedRetrospective StudiesbiologyOncogenebusiness.industryGeneral NeuroscienceCancerRetrospective cohort studyMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticTreatment OutcomeEstrogenLymphatic Metastasisbiology.proteinImmunohistochemistryFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases.

1996

Abstract Background/Aims: Antinuclear antibodies (ANA) are a diagnostic of various autoimmune diseases and also of autoimmune hepatitis type 1. The designation ANA describes a heterogeneous group of autoantibodies. In liver diseases, only a few nuclear target antigens have been molecularly identified and characterized. Cyclins play a central role in a cell cycle regulation, DNA transcription, and cell proliferation. Cyclin A was also identified as an integration site of the hepatitis B virus in a patient with hepatocellular carcinoma. In this study we identify cyclin A as a novel nuclear target protein of ANA. Methods: Sera of patients with autoimmune hepatitis (AIH) type 1 ( n =61), type 2…

AdultPathologymedicine.medical_specialtyAnti-nuclear antibodyCyclin ABlotting WesternImmunoblottingEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisImmunofluorescenceAutoantigensAutoimmune DiseasesMixed connective tissue diseaseimmune system diseasesCyclinsMedicineHumansLupus Erythematosus Systemicskin and connective tissue diseasesFluorescent Antibody Technique IndirectAutoantibodiesAutoimmune diseaseHepatologymedicine.diagnostic_testbiologybusiness.industryLiver DiseasesAutoantibodyDNAMiddle Agedmedicine.diseaseRecombinant ProteinsAntibodies AntinuclearImmunologybiology.proteinAntibodybusinessBaculoviridaeJournal of hepatology
researchProduct

Immunohistochemical localization of filaggrin in benign, premalignant and malignant cervical tissue.

1994

Epithelial distribution of filaggrin, a histidine-rich protein related to squamous terminal differentiation, was investigated in 87 cervical biopsies using an avidin-biotin-peroxidase technique with a monoclonal anti-human filaggrin antibody (AKH1). Normal squamous cervical epithelium exhibited a positive homogeneous immunoperoxidase stain in the upper parabasal, intermediate and superficial cell layers. Similar findings were obtained in cervical condylomas, although full-thickness staining was observed in 35.7% of the cases (P < 0.001). Filaggrin expression in CIN was inversely related to the severity of the lesion (P < 0.001). An irregular staining pattern was present in most high-grade C…

AdultPathologymedicine.medical_specialtySquamous DifferentiationUterine Cervical NeoplasmsCervix UteriFilaggrin ProteinsLesionImmunoenzyme TechniquesUterine Cervical DiseasesIntermediate Filament ProteinsPredictive Value of TestsmedicineBiomarkers TumorHumansskin and connective tissue diseasesCervixintegumentary systemImmunoperoxidasebusiness.industryObstetrics and GynecologyGeneral MedicineUterine Cervical DysplasiaEpitheliumStainingmedicine.anatomical_structureCondylomata AcuminataCarcinoma Squamous CellImmunohistochemistryFemalemedicine.symptomEpidermisbusinessPrecancerous ConditionsCarcinoma in SituFilaggrin
researchProduct

Severe chronic spontaneous urticaria in children – treatment options according to the guidelines and beyond – a 10 years review

2020

This is a retrospective study of 18 children with chronic spontaneous urticaria (CSU), where standard therapies, including up-dosing of antihistamines and omalizumab, were unable to cure the disease and where alternative strategies with experimental and off-label medication had to be used. Being aware that our questionnaire is validated only for elder children or adults, we utilized the UAS7 to monitor disease control with the help of the parents. The UAS7 score decreased from a mean of 25 to an average of 13 after 8 weeks of therapy in 13 patients. Five patients had no significant reduction of UAS7 by week 8. In two of five patients, where periodic improvement was seen, omalizumab therapy …

AdultPediatricsmedicine.medical_specialtyUrticariaDermatologyOmalizumabOmalizumab030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseasesAnti-Allergic AgentsmedicineHumansChronic Urticariaskin and connective tissue diseasesChildAgedRetrospective Studies030203 arthritis & rheumatologybusiness.industryTreatment optionsRetrospective cohort studyDupilumabhumanitiesbody regionsTreatment OutcomeChronic Diseasebusinessmedicine.drug
researchProduct

Complete functional C1q deficiency associated with systemic lupus erythematosus (SLE).

1993

SUMMARY A complete functional deficiency of Clq is described in a patient suffering from SLE. From reduced plasma C1 activity of the parents a hereditary trait was assumed. The defective C1q molecule was haemolytically inactive, did not bind to immune complexes, and was not recognized by the monocyte C1q receptor. C1 activity in the patient's serum could be restored by the addition of purified C1q. Analysis by gelfiltration and ultracentrifugation experiments revealed an immunoreactive molecule of about 150 kD mol. wt, corresponding to one structural subunit of the C1q macromolccule, containing two A chain-B chain dimers and a C-C chain dimer. Applying Southern blot analysis with cDNA clone…

AdultProtein subunitImmunologychemical and pharmacologic phenomenaIn Vitro TechniquesMitochondrial Proteinsimmune system diseasesComplementary DNAmedicineImmunology and AllergyHumansLupus Erythematosus SystemicReceptorskin and connective tissue diseasesSouthern blotLupus erythematosusMembrane Glycoproteinsbusiness.industryMonocyteComplement C1qDNAComplement deficiencymedicine.diseasePrecipitin TestsReceptors ComplementMolecular Weightmedicine.anatomical_structureHyaluronan ReceptorsImmunologyFemaleRestriction fragment length polymorphismbusinessCarrier ProteinsPolymorphism Restriction Fragment LengthResearch Article
researchProduct

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

2010

Background: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer. Methods: Osteopontin, ALCAM, HER2 and ER mRNA expression in breast cancer tissues of 481 patients were analysed (mRNA microarray analysis, kinetic RT–PCR). Hierarchical clustering was performed in training cohort A (N=100, adjuvant treatment) and validation cohorts B (N=200, no adjuvant treatment, low-risk) and C (N=181, adjuvant treatment, high-risk). Results: Negative/low ER and HER2, high OPN and low ALCAM mRNA expression helped to identify patients at particularly h…

AdultRiskCancer ResearchosteopontinReceptor ErbB-2Eukaryotic Initiation Factor-3discriminative markersBreast NeoplasmsDisease-Free SurvivalHER2 and ER-negative breast cancerBreast cancerActivated-Leukocyte Cell Adhesion MoleculemedicineCluster AnalysisHumansOsteopontinRNA MessengerReceptorskin and connective tissue diseasesMolecular DiagnosticsALCAMALCAMAgedOligonucleotide Array Sequence AnalysisbiologyCell adhesion moleculeDecision TreesActivated-Leukocyte Cell Adhesion MoleculeCancerMiddle Agedmedicine.diseasePrognosisOncologyReceptors EstrogenImmunologybiology.proteinCancer researchFemaleBreast diseaseBritish journal of cancer
researchProduct

Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.

2003

Tamoxifen exhibits agonistic properties on the uterus. We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.

AdultSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyAntineoplastic Agents HormonalEndometriosisUterusEndometriosisBreast NeoplasmsCarcinomamedicineHumansskin and connective tissue diseasesGynecologybusiness.industryCarcinoma Ductal BreastObstetrics and GynecologyDuctal carcinomamedicine.diseaseAntiestrogenAbdominal PainOvarian CystsTamoxifenmedicine.anatomical_structureReproductive MedicinePremenopauseAcute abdomenAcute DiseaseFemalemedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

2008

Established histopathological criteria divide invasive breast carcinomas into defined groups. Ductal of no specific type and lobular are the two major subtypes accounting for around 75 and 15% of all cases, respectively. The remaining 10% include rarer types such as tubular, cribriform, mucinous, papillary, medullary, metaplastic, and apocrine breast carcinomas. Molecular profiling technologies, on the other hand, subdivide breast tumors into five subtypes, basal-like, luminal A, luminal B, normal breast tissue-like, and ERBB2-positive, that have different prognostic characteristics. An additional subclass termed "molecular apocrine" has recently been described, but these lesions did not ex…

AdultSilver StainingBreast NeoplasmsBiologyProteomicsBiochemistrySubclassAnalytical ChemistryImmunophenotypingCohort StudiesBreast cancerCoenzyme A LigasesmedicineBiomarkers TumorHumansElectrophoresis Gel Two-DimensionalNeoplasm Invasivenessskin and connective tissue diseasesMolecular BiologyAgedAged 80 and overTissue microarrayParaffin EmbeddingApocrineMiddle Agedmedicine.diseaseImmunohistochemistryApocrine GlandsPhenotypeTissue Array AnalysisImmunologyCancer researchDisease ProgressionHydroxyprostaglandin DehydrogenasesImmunohistochemistryFemaleApocrine CellBreast carcinomaMolecularcellular proteomics : MCP
researchProduct

Hereditary Angioedema Associated with Subacute Cutaneous Lupus Erythematosus

1989

The increased occurrence of various autoimmune diseases has recently been reported in patients with hereditary angioedema (HAE). This is especially the case in different forms of lupus erythematosus, but also other autoimmune diseases. We report a 24-year-old female patient who 10 years ago developed the clinical symptoms of HAE which occurred at the same time as subacute cutaneous lupus erythematosus. The results of both immunological investigations and histocompatibility antigen genotyping gave no clear insight into the causal interrelationship of both diseases.

AdultSystemic diseaseLupus erythematosusAngioedemabusiness.industryDermatologymedicine.diseaseHistocompatibilitySubacute cutaneous lupus erythematosusimmune system diseasesImmunopathologyImmunologyHereditary angioedemaLupus Erythematosus CutaneousmedicineHumansFemaleAngioedemamedicine.symptomskin and connective tissue diseasesbusinessAnti-SSA/Ro autoantibodiesDermatology
researchProduct